Antibodies determined cancer risk in dermatomyositis patients Healio Testing sera in patients with dermatomyositis determined that antibodies to anti-transcriptional intermediary factor-1 and nuclear matrix protein NXP-2 were present in most cancer-associated patients, according to recent study results. “For the ... |
